Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.
Saved in:
| Title: | Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial. |
|---|---|
| Authors: | Perkovic V; University of New South Wales, Sydney., Trimarchi H; Hospital Británico, Buenos Aires., Tesar V; Charles University, Prague, Czech Republic., Lafayette R; Stanford University Medical Center, Stanford, CA., Wong MG; Concord Repatriation General Hospital, Concord, NSW, Australia., Barratt J; University of Leicester, Leicester, United Kingdom., Suzuki Y; Juntendo University Faculty of Medicine, Tokyo., Liew A; Mount Elizabeth Novena Hospital, Singapore., Zhang H; Peking University First Hospital, Beijing., Carroll K; KJC Statistics, Cheadle, United Kingdom., Jha V; George Institute for Global Health, UNSW, New Delhi, India.; School of Public Health, Imperial College London, London.; Manipal Academy of Higher Education, Manipal, India., Quevedo A; Investigación Clinica Aplicada SRL, Buenos Aires., Han SH; Yonsei University College of Medicine, Seoul, South Korea., Praga M; Department of Medicine, Complutense University, Madrid., Chacko B; Nephrology and Transplantation, John Hunter Hospital and University of Newcastle, Newcastle, NSW, Australia., Sahay M; Osmania General Hospital, Hyderabad, India., Cheung CK; University of Leicester, Leicester, United Kingdom., Kooienga L; Colorado Kidney Care, Denver., Walsh M; Department of Medicine, McMaster University, Hamilton, ON, Canada.; Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada., Xia J; Otsuka Pharmaceutical Development and Commercialization, Princeton, NJ., Fajardo C; Otsuka Pharmaceutical Development and Commercialization, Princeton, NJ., Shah L; Otsuka Pharmaceutical Development and Commercialization, Princeton, NJ., Hafkin J; Otsuka Pharmaceutical Development and Commercialization, Princeton, NJ., Rizk DV; Division of Nephrology, Department of Medicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham. |
| Corporate Authors: | VISIONARY Trial Investigators Group |
| Source: | The New England journal of medicine [N Engl J Med] 2026 Feb 12; Vol. 394 (7), pp. 635-646. Date of Electronic Publication: 2025 Nov 08. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study |
| Journal Info: | Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41211929 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Perkovic+V%22">Perkovic V</searchLink>; University of New South Wales, Sydney.<br /><searchLink fieldCode="AU" term="%22Trimarchi+H%22">Trimarchi H</searchLink>; Hospital Británico, Buenos Aires.<br /><searchLink fieldCode="AU" term="%22Tesar+V%22">Tesar V</searchLink>; Charles University, Prague, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Lafayette+R%22">Lafayette R</searchLink>; Stanford University Medical Center, Stanford, CA.<br /><searchLink fieldCode="AU" term="%22Wong+MG%22">Wong MG</searchLink>; Concord Repatriation General Hospital, Concord, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Barratt+J%22">Barratt J</searchLink>; University of Leicester, Leicester, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Suzuki+Y%22">Suzuki Y</searchLink>; Juntendo University Faculty of Medicine, Tokyo.<br /><searchLink fieldCode="AU" term="%22Liew+A%22">Liew A</searchLink>; Mount Elizabeth Novena Hospital, Singapore.<br /><searchLink fieldCode="AU" term="%22Zhang+H%22">Zhang H</searchLink>; Peking University First Hospital, Beijing.<br /><searchLink fieldCode="AU" term="%22Carroll+K%22">Carroll K</searchLink>; KJC Statistics, Cheadle, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Jha+V%22">Jha V</searchLink>; George Institute for Global Health, UNSW, New Delhi, India.; School of Public Health, Imperial College London, London.; Manipal Academy of Higher Education, Manipal, India.<br /><searchLink fieldCode="AU" term="%22Quevedo+A%22">Quevedo A</searchLink>; Investigación Clinica Aplicada SRL, Buenos Aires.<br /><searchLink fieldCode="AU" term="%22Han+SH%22">Han SH</searchLink>; Yonsei University College of Medicine, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Praga+M%22">Praga M</searchLink>; Department of Medicine, Complutense University, Madrid.<br /><searchLink fieldCode="AU" term="%22Chacko+B%22">Chacko B</searchLink>; Nephrology and Transplantation, John Hunter Hospital and University of Newcastle, Newcastle, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Sahay+M%22">Sahay M</searchLink>; Osmania General Hospital, Hyderabad, India.<br /><searchLink fieldCode="AU" term="%22Cheung+CK%22">Cheung CK</searchLink>; University of Leicester, Leicester, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Kooienga+L%22">Kooienga L</searchLink>; Colorado Kidney Care, Denver.<br /><searchLink fieldCode="AU" term="%22Walsh+M%22">Walsh M</searchLink>; Department of Medicine, McMaster University, Hamilton, ON, Canada.; Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Xia+J%22">Xia J</searchLink>; Otsuka Pharmaceutical Development and Commercialization, Princeton, NJ.<br /><searchLink fieldCode="AU" term="%22Fajardo+C%22">Fajardo C</searchLink>; Otsuka Pharmaceutical Development and Commercialization, Princeton, NJ.<br /><searchLink fieldCode="AU" term="%22Shah+L%22">Shah L</searchLink>; Otsuka Pharmaceutical Development and Commercialization, Princeton, NJ.<br /><searchLink fieldCode="AU" term="%22Hafkin+J%22">Hafkin J</searchLink>; Otsuka Pharmaceutical Development and Commercialization, Princeton, NJ.<br /><searchLink fieldCode="AU" term="%22Rizk+DV%22">Rizk DV</searchLink>; Division of Nephrology, Department of Medicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham. – Name: AuthorCorporate Label: Corporate Authors Group: Au Data: <searchLink fieldCode="CA" term="%22VISIONARY+Trial+Investigators+Group%22">VISIONARY Trial Investigators Group</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%220255562%22">The New England journal of medicine</searchLink> [N Engl J Med] 2026 Feb 12; Vol. 394 (7), pp. 635-646. <i>Date of Electronic Publication: </i>2025 Nov 08. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Massachusetts+Medical+Society%22">Massachusetts Medical Society </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0255562 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1533-4406 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200284793%22">00284793 </searchLink><i>NLM ISO Abbreviation: </i>N Engl J Med <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41211929 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1056/NEJMoa2512133 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 635 Titles: – TitleFull: Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Perkovic V – PersonEntity: Name: NameFull: Trimarchi H – PersonEntity: Name: NameFull: Tesar V – PersonEntity: Name: NameFull: Lafayette R – PersonEntity: Name: NameFull: Wong MG – PersonEntity: Name: NameFull: Barratt J – PersonEntity: Name: NameFull: Suzuki Y – PersonEntity: Name: NameFull: Liew A – PersonEntity: Name: NameFull: Zhang H – PersonEntity: Name: NameFull: Carroll K – PersonEntity: Name: NameFull: Jha V – PersonEntity: Name: NameFull: Quevedo A – PersonEntity: Name: NameFull: Han SH – PersonEntity: Name: NameFull: Praga M – PersonEntity: Name: NameFull: Chacko B – PersonEntity: Name: NameFull: Sahay M – PersonEntity: Name: NameFull: Cheung CK – PersonEntity: Name: NameFull: Kooienga L – PersonEntity: Name: NameFull: Walsh M – PersonEntity: Name: NameFull: Xia J – PersonEntity: Name: NameFull: Fajardo C – PersonEntity: Name: NameFull: Shah L – PersonEntity: Name: NameFull: Hafkin J – PersonEntity: Name: NameFull: Rizk DV IsPartOfRelationships: – BibEntity: Dates: – D: 12 M: 02 Text: 2026 Feb 12 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1533-4406 Numbering: – Type: volume Value: 394 – Type: issue Value: 7 Titles: – TitleFull: The New England journal of medicine Type: main |
| ResultId | 1 |